Investigational drug · Phase 2
SIPI6398
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Schizophrenia Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SIPI6398"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SIPI6398", any sponsor or status.
Conditions studied
As listed on its trial records.
- Schizophrenia Disorder
Approved drugs for the same conditions: Schizophrenia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "SIPI6398" as an intervention, largest first.
- A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398Not yet recruiting
Shanghai Zhongze Therapeutics Co., Ltd.Industry
NCT07626034 · 9 participants (planned) · Start Aug 2026 · Primary completion Oct 2027
Drug: SIPI6398 Tablets · For: Schizophrenia Disorder
Newest research
PubMed records naming it or its code names, newest first.
- Advanced UPLC-MS/MS Method for the Quantification of SIPI6398 in Rat Plasma and Its Pharmacokinetic Characterization.
Chen F, Ma S, Wang R, et al. · J Anal Methods Chem 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.